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Abstract 
 
As rates of skin cancer continue to rise, sunscreen continues to be an essential tool in the 
fight against harmful UV radiation emanating from the sun.  Sunscreen labeling greatly impacts 
the public’s perception of the risks of sun exposure, the protection obtained from a particular 
product, and the proper use of sunscreen.  Thus, FDA regulation of sunscreen to prevent 
misleading labeling is an important aspect of public health.  FDA began the rulemaking process 
for sunscreen products in 1978, but has yet to issue a final monograph that would legally bind 
sunscreen manufacturers.  This prolonged rulemaking has resulted in many conclusions and 
proposed rules that would regulate sunscreen labels in order to encourage proper understanding 
of sun exposure danger and proper use of sunscreen products.  However, since the regulations 
are not binding, manufacturers need not comply with FDA’s rules.  Thus, the public has not 
benefited from FDA’s thorough analyses and proposed solutions to labeling, but instead has 
suffered and continues to suffer from FDA inaction.1 
Introduction 
 
Sunscreen has long been a staple of American outdoor activity.  As we move further into 
the twenty-first century, it seems certain that the desire for tan skin and sun soaking vacations is 
here to stay.  And it also seems clear that skin cancer is here to stay.  The incidence rate of 
melanoma has been increasing for the past thirty years.
1  As of 2006, its incidence rate has 
increased over 500% in the previous fifty years, which is the fastest increase of any cancer type.
2  
Rates of the more common, but less deadly, basal and squamous cell skin cancers have also been 
on the rise for many years.
3  In fact, skin cancer is by far the most common type of cancer,
4 and 
thus presents an immediate challenge to our country.  As our understanding of the sun’s potential 
to damage our health grows, our reliance on sunscreen products increases.  This is evident in the 
seemingly endless climb of SPF values of sunscreen products.
5  Demand exists for products that 
advertise strong sun protection; but as Americans attempt to take control of their health in the 
drug store aisle, are they being misled by the numerous bottles that attempt to lure them into a 
purchase?   
Each time a person applies sunscreen and steps outside, she is implicitly performing a 
cost-benefit analysis to decide if her activity is worth the risks of the sun.  Yet the knowledge she 
relies on to make this decision is likely confined to the few recognizable terms on the bottle of 
sunscreen.  A popular Neutrogena sunscreen states that it is “ultra sheer dry-touch sunblock.”
6  
This raises a number of questions.  How can “dry-touch” be used to describe a liquid sunscreen?  
                                                 
1 American Cancer Society, http://www.cancer.org/Cancer/SkinCancer-Melanoma/DetailedGuide/melanoma-skin-
cancer-key-statistics (last visited May 3, 2011). 
2 Melody J. Eide & Martin A. Weinstock, Public Heath Challenges in Sun Protection, 24 DERMATOLOGICAL 
CLINICS 119, 119 (2006). 
3 American Cancer Society, http://www.cancer.org/Cancer/SkinCancer-BasalandSquamousCell/DetailedGuide/skin-
cancer-basal-and-squamous-cell-key-statistics (last visited May 3, 2011). 
4 Id. 
5 See Uli Osterwalder & Bernd Herzog, The Long Way Towards the Ideal Sunscreen—Where We Stand and What 
Still Needs To Be Done, 9 PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES 470, 477 (2010). 
6 Neutrogena Ultra Sheer Dry-Touch Sunblock SPF 80+ 2 
What is sunblock?  Will this sunscreen actually block the sun’s rays from the skin?  Is it better 
than a bottle labeled “sunscreen”?  What does “SPF 85+” mean?  Is this value as much of an 
improvement over SPF 30 as it seems?  What does “broad spectrum uva-uvb” mean?  Does this 
product fully and equally protect against UVA and UVB radiation?  Furthermore, what does 
“waterproof” actually mean?  Does water have any effect on the strength of this sun protection?  
Are all “waterproof” sunscreens comparable?  Why do other sunscreen products contain labels 
stating “water resistant”?  What about sweat?  Perhaps consumers believe these terms simply 
mean what they seem to.  After all, the Food and Drug Administration (FDA) must have 
regulations to protect consumers from being misled about such an essential health product. 
In reality, sunscreen exists in a regulatory grey area.  FDA recognizes it as an over the 
counter (OTC) drug, and it has been the subject of mostly unfinalized rulemaking since 1978.
7  
Thus, in spite of thorough analyses and conclusions regarding many labeling issues, sunscreen 
manufacturers are not subject to FDA enforcement on these issues.  Of course, sunscreen is still 
subject to broader legislation regarding safety and misbranding,
8 but most of the detailed 
sunscreen regulations that have been written are not in effect.  While FDA sorts through 
continuous scientific research, the public is left largely to the advertising whims of sunscreen 
manufacturers and executives.   
This paper will address the regulatory background that has led to this state of uncertainty, 
the large labeling issues that continue to place consumers at risk, and the potential future effects 
of FDA inaction.  It concludes that the failure to finalize sunscreen regulations has deprived the 
public of health protection and knowledge.  By delaying the implementation of rules in order to 
                                                 
7 FDA Rulemaking History for OTC Sunscreen Drug Products, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-
CounterOTCDrugs/StatusofOTCRulemakings/ucm072134.htm (last visited May 3, 2011). 
8 Sunscreen Drug Products for Over-The-Counter Use; Final Monograph, 64 Fed. Reg. 27666, 27668 (May 21, 
1999). 3 
wait for state of the art science, FDA has withheld valuable labeling protections from the public.  
The future remains uncertain, but Americans would benefit from an imminent resolution. 
 
Sunscreen Basics 
In the advance notice of proposed rulemaking issued in 1978, FDA concluded that over-
exposure to the sun damages the skin and can lead to skin lesions and skin cancer.
9  As it is now 
widely known, sunscreen provides protection from many harmful effects of the sun, such as 
photoaging and skin cancer.
10  Sunscreen products absorb, reflect, or scatter ultraviolet (UV) 
waves that deliver harmful radiation to the skin, thereby decreasing the amount of radiation that 
would otherwise be exposed to the skin.
11  The sun protection factor (SPF) is the standard 
measurement for UVB radiation effects, as it measures erythema, commonly referred to as 
sunburn, caused by UV radiation.
12  UVA protection, which can be evaluated by many different 
efficacy tests, is typically referred to in more qualitative terms, such as “broad spectrum” 
protection.
13  Thus, sunscreen products affect the way that UV radiation interacts with the body 
in an effort to decrease the harmful effects of exposure to sunlight.  
One legal aspect of sunscreen is clear: it is classified as a drug under the Federal Food, 
Drug, and Cosmetic Act (FD&C Act).
14  The FD&C Act provides that “drugs” include “articles 
intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or 
other animals,” as well as “articles (other than food) intended to affect the structure or any 
                                                 
9 Sunscreen Drug Products for Over-The-Counter Human Use, Notice of Proposed Rulemaking, 43 Fed. Reg. 
38206, 38209 (Aug. 25, 1978). 
10 Eide, supra note 2, at 119. 
11 J F. Nash, Paul R. Tanner & Paul J. Matts, Ultraviolet A Radiation: Testing and Labeling for Sunscreen Products, 
24 DERMATOLOGIC CLINICS 63, 63 (2006). 
12 Id.  
13 Id. 
14 Sunscreen Drug Products for Over-The-Counter Use; Final Monograph, 64 Fed. Reg. 27666, 27668 (May 21, 
1999). 4 
function of the body of man or other animals.”
15  FDA has concluded that sunscreen may help 
reduce the risk of skin lesions, cancer, and other diseases, and that active ingredients in 
sunscreen affect the structure and function of the body by absorbing, reflecting, or scattering rays 
of the sun and thus changing the physiological response to solar radiation.
16  Furthermore, FDA 
has concluded that the key to a sunscreen’s classification as a drug is the presence of a sunscreen 
active ingredient, in conjunction with labeling claims that the product affects the structure or 
function of the body.
17  Therefore, tanning products that claim to affect the function of the body, 
as well as other products such as lipsticks and moisturizers that contain sunscreen are all 
classified as drugs.
18   
In spite of clear statements from FDA affirming that sunscreen is a drug, comments were 
still submitted in response to the tentative final monograph of 1993 that suggested sunscreen 
should be regulated as a cosmetic.
19  Nonetheless, FDA appears committed to the current 
classification, as the designation of cosmetics containing sunscreen with sunscreen terminology 
was codified in the final monograph of 1999.
20  In addition, FDA added a requirement of a 
warning statement on suntanning preparations that do not contain a sunscreen ingredient.
21  
These items include products that intend to give the appearance of a tan through either UV 
radiation exposure or color additives.
22  The label must warn consumers that the product does not 
contain a sunscreen, the product does not protect against burn, and that exposure of unprotected 
                                                 
15 21 U.S.C. § 321(g)(1)(B); 21 U.S.C. 321(g)(1)(C) (2008). 
16 64 Fed. Reg. at 27668. 
17 Id. 
18 Id. 
19 Id. 
20 21 C.F.R. § 700.35 (1999).  While the bulk of the 1999 Final Monograph was stayed, this section, addressing 
cosmetics containing sunscreen, was placed in effect.  Id. 
21 21 C.F.R. § 740.19 (1999). 
22 Id. 5 
skin while tanning may increase the risk of skin cancer, even if the skin does not burn.
23  FDA, 
therefore, has taken a firm stance on the classification of sunscreen as a drug.  Through the 
labeling requirements of cosmetics that do not contain sunscreen, FDA has taken concrete steps 
to assist consumers in distinguishing between products that are drugs and those that are merely 
cosmetics that do not provide sun protection.  It has not, however, taken similarly strong steps in 
assisting the public once the drug classification has been made. 
 
The OTC Monograph Scheme and Sunscreen’s Procedural Complications 
  FDA has set up a regulatory procedure to classify OTC drugs as generally recognized as 
safe and effective and not misbranded.  In order to accommodate the vast amount of products, 
many of which are similar to one another, FDA created a process to approve drugs that are 
generally recognized as safe by category in 1972.
24  This allowed generally safe drugs to bypass 
the new drug application (NDA) process, which can be burdensome and expensive.  Through the 
use of advisory panels, data review, and public comments, FDA created a procedure to establish 
monographs for OTC drugs.
25   
The monographs establish conditions under which a particular drug can be recognized as 
safe and effective and not misbranded.
26  The conditions may include active ingredients, labeling 
indications, warnings, adequate directions for use, and other conditions relating to the safety and 
effectiveness of the drug.
27  They are established through a lengthy process, whereby the 
advisory panels recommend a monograph to the Commissioner, who then publishes a proposed 
                                                 
23 Id. 
24 Sunscreen Drug Products for Over-The-Counter Human Use, Notice of Proposed Rulemaking, 43 Fed. Reg. 
38206, 38206-07 (Aug. 25, 1978). 
25 21 C.F.R. § 331.10 (2010). 
26 21 C.F.R. § 331.10(a)(5)(i) (2010). 
27 Id. 6 
monograph in the Federal Register.  After receiving and reviewing comments to the proposed 
monograph, a tentative final monograph is published in the Federal Register.  After an additional 
round of comments and a potential for an oral hearing, the Commissioner publishes a final 
monograph in the Federal Register.
28 
The process of regulating sunscreen through the OTC monograph scheme has been quite 
lengthy.  In 1978 FDA issued an advance notice of proposed rulemaking for sunscreen drug 
products in the Federal Register.
29  Following this notice, a slew of procedural hurdles followed: 
extension of the comment period, corrections, reopening of the administrative record, public 
meetings, and so forth.
30  In 1993 FDA published the tentative final monograph for sunscreen, 
and then in 1999 the final monograph was issued.
31   
In 2001 however, before the date on which the monograph was to become effective, FDA 
issued a partial stay of the rule.  The bulk of the monograph fell into the “partial” description, 
thereby leaving numerous labeling regulations suggested, but not required.
32  FDA stated that it 
made the decision to stay the rule in order to address formulation, labeling, and testing 
requirements for UVA and UVB protection and create a comprehensive sunscreen final 
monograph.
33  This effort to be comprehensive, however, has pushed back the implementation of 
important regulations that are unrelated to the UVA and UVB issues. 
 
 
 
                                                 
28 21 C.F.R. § 331.10 (2010). 
29 43 Fed. Reg. at 38206. 
30 FDA Rulemaking History for OTC Sunscreen Drug Products, 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Over-the-
CounterOTCDrugs/StatusofOTCRulemakings/ucm072134.htm (last visited May 3, 2011). 
31 Id. 
32 Sunscreen Drug Products for Over-the-Counter Human Use; Partial Stay, 66 Fed. Reg. 67485, 67485 (2001). 
33 66 Fed. Reg. at 67485. 7 
The 1999 Final Monograph 
The final monograph that was released in 1999 incorporated provisions from the tentative 
final monograph, in addition to provisions addressing comments to the tentative final 
monograph, that provided great benefits to consumers.  FDA’s conclusions to the comments 
received as well as the actual monograph contain many provisions and statements regarding 
sunscreen labeling policies.  The following discussion presents an examination of some of the 
labeling decisions set forth in the final monograph.  
One major change that was to be implemented in the 1999 final monograph was a new 
SPF labeling scheme.  In spite of numerous comments objecting to the change, FDA concluded 
that “an SPF 30 sunscreen product provides adequate protection for the majority of consumers 
even under extreme conditions, less than ideal usage, or in varying weather conditions.”
34  An 
SPF 50 sunscreen provides only about a 1.3 percent increase in absorption of erythemal UV 
radiation, and FDA stated it believed that the nonlinearity of the SPF rating system is confusing 
to consumers and would be difficult to explain through labeling.  Furthermore, it doubted the 
ability of current testing models to accurately measure high SPF values.  Therefore, FDA 
concluded that all SPF values above 30 should be labeled either “30+” or “30 plus,” and any 
product labeled with a higher SPF value would be considered misbranded, in violation of the 
FD&C Act.
35  At the same time, FDA stated that it “invites interested persons to continue 
developing the test methods needed to measure high SPF values, and to submit the data in 
support of such methods to FDA.”
36   
                                                 
34 Sunscreen Drug Products for Over-The-Counter Use; Final Monograph, 64 Fed. Reg. 27666, 27674 (May 21, 
1999). 
35 64 Fed. Reg. at 27675. 
36 64 Fed. Reg. at 27675. 8 
Those opposed to the SPF labeling requirement have argued that there is a lack of data 
suggesting a link between high SPF values and safety problems, there is a benefit of high SPF 
products for people with very sensitive skin, and there are new formulations that achieve high 
SPF products with lower active ingredient concentrations.
37  It has also been argued that FDA’s 
policy to prevent a race to the top of SPF levels is paternalistic and greatly interferes with 
consumer autonomy.
38  While these arguments of the opposition are valid, ultimately the 
decision to limit the labeling to “30+” was a wise decision.  SPF is arguably the defining factor 
of a sunscreen and “the driving force behind the choice of sunscreen product.”
39  While products 
do not generally explain what SPF even means, the number is a simple way to quantify a 
sunscreen’s worth.  An SPF 85 sunscreen does not appear to be only minimally superior to an 
SPF 30 sunscreen.  The high value could easily lead some wearers to be less diligent in 
reapplying a product that appears more potent than it is.  Additionally, as noted by FDA, 
perception of sunburn protection should not be limited to SPF value.  An optimal balance of 
factors is needed, including irritation potential and UVA radiation protection.
40  Allowing SPF 
values to soar creates an undue emphasis on that single factor, which is particularly dangerous 
for consumers given the unintuitive incremental benefits of high SPF values in addition to 
harmful UVA radiation.  The “30+” decision was, therefore, ultimately a beneficial change to 
sunscreen labeling, considering the level of scientific knowledge available at the time. 
An additional beneficial change to labeling was the regulation of waterproof claims.  The 
final monograph requires products that pass the water resistant testing procedures to be labeled 
either “water resistant” or “water/sweat resistant,” and it requires products that satisfy the very 
                                                 
37 64 Fed. Reg. at 27675. 
38 Perham Gorji, OTC Sunscreen Drug Products: Toward Greater Protection, FOOD AND DRUG LAW: AN 
ELECTRONIC BOOK OF STUDENT PAPERS 1, 12 (1997), http://www.law.harvard.edu/faculty/hutt/book_index.html. 
39 Nash, supra note 11, at 63. 
40 64 Fed. Reg. at 27675. 9 
water resistant testing procedures to be labeled “very water resistant” or “very water/sweat 
resistant.”
41  This mandated terminology would prevent manufacturers from using common 
terms, such as “waterproof.”  FDA discussed this issue thoroughly in the tentative final 
monograph and expressed a concern that “waterproof” could be interpreted as describing 
“something that is completely resistant to water regardless of time of immersion.”
42  Indeed, 
“waterproof” does invite a strong interpretation of the sunscreen’s power to withstand water.  
Furthermore, water resistance is not an indication of ability to withstand friction, as up to 85% of 
sunscreen on the skin can be removed from toweling off.
43  Thus, these sunscreens should still be 
reapplied after swimming, vigorous activity, or toweling.
44  While this word change may be 
subtle, and to some may even appear hypercritical, labeling word choice should be analyzed 
extensively in order to best protect the consumer.  Advertising depends on subtle word choice, 
and FDA should not allow potentially deceptive language on the label of an important health 
product. 
Also on the subject of word choice, the final monograph does not allow potentially 
misleading statements, such as “help[s] prevent skin damage,” since skin damage can occur even 
with the use of sunscreen and without a visible sunburn.
45  Instead the monograph allows a 
product to contain this type of claim only if it adheres to the exact phrase, “Sun alert: Limiting 
sun exposure, wearing protective clothing, and using sunscreens may reduce the risks of skin 
aging, skin cancer, and other harmful effects of the sun.”
46  Furthermore, FDA banned as 
nonmonograph phrases such as “shields from,” “protects from,” “filters,” and “screens out” 
                                                 
41 21 C.F.R. § 352.50. 
42 Sunscreen Drug Products for Over-the-Counter Human Use; Tentative Final Monograph, 58 Fed. Reg. 28194, 
28228 (1993). 
43 Patricia Poh Agin, Water Resistance and Extended Wear Sunscreens, 24 DERMATOLOGIC CLINICS 75, 76 (2006). 
44 Id. 
45 64 Fed. Reg. at 27676-77. 
46 21 C.F.R. § 352.52(e)(2). 10 
because they suggest a false sense of protection.
47  FDA also decided to ban the term “sunblock” 
as nonmonograph due to concern that the word may be viewed as an absolute term implying that 
it blocks all light from the sun.
48  These detailed regulations together work to create an honest 
and balanced tone on sunscreen labeling.  The benefits of sunscreen should surely be praised, but 
sunscreen products also should not lure customers into a false sense of security. 
An additional labeling change set forth in the final monograph is a set of three product 
categories to accompany SPF values: minimal sunburn protection (for products with SPF 2 to 
under 12), moderate sunburn protection (for products with SPF 12 to under 30), and high 
sunburn protection (for products with SPF 30 and higher).
49  These categories were reduced from 
the earlier proposed five categories and also removed proposed language referencing the 
prevention of tanning.
50  The ranking of SPF values, while arguably superfluous, further shows 
an effort to reach the public in a simple and informative way.  This simple explanation shows a 
great improvement from the unregulated use of very large SPF values that could easily mislead 
consumers.  In sum, the labeling regulations in the final monograph represent FDA’s 
commitment to provide safe and clear information for the public.  Nevertheless, in spite of the 
abundant consumer friendly provisions, in 2001 FDA issued a stay of the majority of the final 
monograph.
51 
 
 
 
 
                                                 
47 64 Fed. Reg. at 27677. 
48 64 Fed. Reg. at 27680. 
49 64 Fed. Reg. at 27679. 
50 64 Fed. Reg. at 27679. 
51 Sunscreen Drug Products for Over-the-Counter Human Use; Partial Stay, 66 Fed. Reg. 67485 (2001). 11 
The 2007 Proposed Rules 
  The 2007 proposed rules most notably reflect FDA’s prior stated concern about the lack 
of an adequate UVA test.  From among the more than ten different UVA tests,
52 FDA has chosen 
two required tests to determine a sunscreen’s UVA rating.  It proposes both an in vitro and in 
vivo test to be performed on each product, with a rating adopting the lower of the two test 
results.
53  The rating will consist of both stars and a category descriptor, with the categories 
“low,” “medium,” “high,” and “highest” each corresponding respectively to one, two, three, or 
four stars.
54  Thus, if a sunscreen scored a medium on the in vitro test and a high on the in vivo 
test, the product would display a UVA score of medium with a picture of two stars.  This rating 
will be displayed in an equally prominent manner as the UVB/SPF rating, in spite of comments 
claiming that UVB radiation is still more of a concern than UVA radiation.
55  Additionally, a 
product with no adequate UVA protection will be required to have labeling that states, “no UVA 
protection.”
56   
Some people still maintain that SPF should be the most prominent indicator on sunscreen 
labels based on the claim that most UV-induced skin damage is a result of short wavelength 
UVB radiation.
57  These advocates support a simple broad spectrum designation for products 
with UVA protection, so as to not detract from the SPF value.
58  By rejecting these UVB-centric 
proposals, the FDA has affirmed its assessment of the importance of UVA protection and the 
need for sunscreen products to more adequately address the full spectrum of radiation and sun 
                                                 
52 FDA Press Conference on Issues Related to Sunscreens, at 4 (Aug. 23, 2007). 
53 Sunscreen Drug Products for Over-the-Counter Human Use; Proposed Amended Final Monograph, 72 Fed. Reg. 
49070, 49104 (Aug. 27, 2007). 
54 72 Fed. Reg. at 49083. 
55 72 Fed. Reg. at 49083. 
56 72 Fed. Reg. at 49112. 
57 Nash, supra note 11, at 70. 
58 Id. at 71. 12 
induced skin dangers.  This conclusion is supported by much evidence and worldwide consensus, 
as studies have shown that exposure to long wavelength UVA radiation damages the skin and 
can lead to cancer.
59 
  Not only does evidence exist showing the need for UVA protection independent of other 
factors, but some studies support the “compensation hypothesis,” which holds that UVB 
protection may actually increase the harmful effects of UVA radiation, such as melanoma.  The 
theory suggests that people can be exposed to UVA radiation longer, based on the UVB 
protection’s effectiveness in preventing the skin from burning.  Without UVB protection, a 
person would not stay in the sun as long and, thus, would be better protected from UVA 
radiation.
60  Evidence exists to both support and refute this hypothesis,
61 but at the very least, the 
hypothesis supports the broader principle that UVB protection does not address the dangers of 
UVA radiation.  The lack of sunburn resulting from exposure to UVA radiation further stresses 
the need to raise UVA awareness and protect skin from effects that are not immediately apparent. 
  The 2007 proposed rules also amend the SPF labeling on sunscreen products.  Rather 
than limiting SPF values to “30+,” the agency is now allowing values up to “50+.”
62  This 
change is related to new testing data showing that the SPF test produces accurate results for 
products between SPF 30 and 50, which was not available at the time of the final monograph.
63  
However, the “30+” labeling restriction of the final monograph was met with some strong 
complaints, which may be applicable to the new “50+” limit as well.  Some comments asserted 
these limits, in addition to some other labeling restrictions, violated the right to freedom of 
                                                 
59 Id. at 65. 
60 Eide, supra note 2, at 120. 
61 Id. at 121. 
62 72 Fed. Reg. at 49072. 
63 72 Fed. Reg. at 49079. 13 
speech guaranteed by the First Amendment of the Constitution.
64  These comments allege that 
FDA has failed to meet its burden to prove that the claims are misleading or that the restrictions 
on the speech directly advance a substantial government purpose.
65  FDA maintains, however, 
that the labeling requirements are “reasonably related to the Government’s interest in promoting 
the health, safety, and welfare of consumers and because they are not an ‘unjustified or unduly 
burdensome’ disclosure requirement.”
66   
FDA presents a strong argument in support of the labeling restrictions.  The comments do 
not appear to appreciate the overall purpose of the monograph process as compared to the NDA 
process.  As discussed earlier, the monograph system is meant to approve drugs that are 
generally recognized as safe and effective.  The labeling requirements prescribed in the 
monograph directly relate to consumer understanding and the safe and effective use of the 
product.
67  Since SPF in particular is such a strong identifying component of sunscreen 
products,
68 a labeling restriction based on scientific data that high SPF values do not supply a 
worthwhile benefit is quite reasonable.  SPF values in the United States reached the extremely 
high level of “100+” in 2009, further highlighting the need to stop the fruitless race to the top.
69  
Perhaps the newly allowed “50+” label will satisfy some of the critics of the “30+” limit.  Since 
SPF values have remained unregulated in spite of the final monograph, high SPF values are quite 
common on store shelves, and so customers used to relying on high SPF values may be more 
accepting of a higher cap. 
                                                 
64 72 Fed. Reg. at 49077. 
65 72 Fed. Reg. at 49077. 
66 72 Fed. Reg. at 49077. 
67 See 72 Fed. Reg. at 49077. 
68 See 72 Fed. Reg. at 49804. 
69 Osterwalder, supra note 5, at 477. 14 
Also relating to UVB labeling, the term “UVB” will now be included before the term 
“SPF,” so that consumers will understand that SPF is only an indicator of UVB protection.
70  The 
SPF values will also have a corresponding category descriptor that adopts the same terms that are 
used to describe UVA values (low, medium, high, and highest).  This change amends the three 
categories adopted in the 1999 final monograph (minimal, moderate, and high).
71  These new 
requirements are practical responses to the new UVA labeling, as using the same rating system 
for both factors will likely present the information in the clearest way possible.  
  In addition, FDA has refined the already carefully analyzed word choice required in the 
final monograph.  The optional “sun alert” statement in the final monograph has been changed to 
a mandatory revised “sun alert” in the “Warnings” section of the label.
72  The mandatory alert 
states, “UV exposure from the sun increases the risk of skin cancer, premature skin aging, and 
other skin damage.  It is important to decrease UV exposure by limiting time in the sun, wearing 
protective clothing, and using a sunscreen.”
73  Additionally, the proposed regulations now will 
only allow manufactures the choice of either “liberally” or “generously” in the directions section 
of the label.  The previously allowed term, “smoothly,” will be eliminated due to vagueness.
74  
Furthermore, the directions will include reapplying instructions, rather than just applying 
instructions.
75   
These instructions attempt to address the particular challenge of encouraging proper use.  
Consumers typically apply less sunscreen than is needed to establish the SPF that manufacturers 
claim, so the actual SPF obtained may only be 20% to 50% of the advertised SPF.
76  One study 
                                                 
70 72 Fed. Reg. at 49077. 
71 72 Fed. Reg. at 49077. 
72 72 Fed. Reg. at 49072. 
73 72 Fed. Reg. at 49072. 
74 72 Fed. Reg. at 49072. 
75 72 Fed. Reg. at 49072. 
76 Eide, supra note 2, at 120. 15 
conducted in Australia found that the median amount of sunscreen applied was 0.8 mg.cm,
2 
which is less than half the amount that was needed to achieve the SPF on the label.
77  
Furthermore, many people do not adequately appreciate the need to reapply sunscreen, 
particularly when it is labeled “waterproof.”
78  This is especially important, given another study 
that found that reapplication of sunscreen produced a benefit two to three times as great as that of 
a single application.
79  Directions and warnings that emphasize these issues could help to educate 
the public and help people maximize the benefits of sunscreen. 
The 2007 proposed rules also address concerns regarding the best way to label cosmetics 
containing sunscreen.  The prevalent use of face makeup advertising SPF levels on product 
labels also has created new challenges to encouraging proper and effective use of these products.  
Cosmetic products containing sunscreen became increasingly popular by the end of the 20
th 
century.
80  Sun protection in foundation is an excellent idea that encourages daily use of sun 
protection, but it also creates an opportunity for inaccurate assumptions based on misleading 
labeling.  For example, foundation tends to migrate on the face, as a study showed that makeup 
tends to collect in facial lines soon after application.
81  An additional study showed that 
foundation migrated within 2 hours or less on women with oily skin and within 4 hours for all of 
the women.
82  Thus, it seems that foundation products may not be as effective as a sunscreen 
with a comparable SPF.  But since SPF is the defining feature of sun protection, most foundation 
wearers likely do not know that their product may not adequately maintain the protection 
advertised on the label. 
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A major concern with makeup products containing sunscreen is improper use and a lack 
of understanding of the limits of its protection.  Foundation is likely not often applied 
“generously,” as sunscreen should be.
83  Some comments to the final monograph note that many 
consumers use face and hand cosmetics containing sunscreen as their primary and sometimes 
only source of sun protection.
84  Thus, labeling on these cosmetics is very likely just as important 
as the labeling on traditional sunscreens.  Others, however, were concerned with accommodating 
the new labeling requirements on small packaging, particularly for products used on only a small 
part of the face, such as lip balm and lipstick.
85  In the proposed rule, FDA struck a balance in 
deciding how to handle these issues.  Specifically it allowed labeling modifications for sunscreen 
products that are labeled for use only on particular small areas of the face and that are sold in 
small packages.
86  This would not include facial foundation, moisturizer, or other products used 
on larger areas of the face.
87   
Requiring the sunscreen warnings and labeling on facial cosmetics is an essential step to 
take toward greater sun protection.  Furthermore, the exemptions for small products only used on 
small areas of the face are sensible, particularly in light of the risk that manufacturers would 
choose to remove all sun protection from small products rather than accommodate burdensome 
labeling requirements.
88  The UVA labeling specifically will help consumers, as labels declaring 
“no UVA protection” will hopefully educate consumers about the fact that SPF is not a 
comprehensive indicator of sun protection.  However, facial cosmetics may be in need of further 
warnings due to foundation’s migration tendencies on the face,
89 and also due to different 
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application practices of foundation as opposed to sunscreen.  Makeup wearers should know that 
applying small amounts of the product lowers the SPF and increases risk of sun damage.  While 
over-labeling could risk turning customers away from reading any of the label, additional 
warnings should at least be considered and further efforts to understand the relative protection of 
foundation as compared to traditional sunscreen should be made. 
  In sum, these new regulations build on the final monograph’s efforts to improve 
sunscreen labeling to best protect consumers.  The inclusion of UVA ratings and detailed 
changes to allowable and mandated language provide a better tool for consumers to make an 
educated choice of sunscreen.  Nonetheless, as time passes without any regulations becoming 
finalized, consumers are unable to receive the benefits of FDA’s conclusions and may be 
harming their health due to misunderstanding of sunscreen labels and the risks of prolonged sun 
exposure. 
 
Effects of FDA’s Failure to Finalize Regulations 
  In 1978, when FDA issued an advance notice of proposed rulemaking for sunscreen 
products, it is hard to imagine the agency would have predicted that final regulations would still 
not exist in 2011.  The establishment of norms and standards is crucial to UV protection.
90   
FDA’s failure to implement final regulations for so long has led to products being sold that do 
not need to conform to the thoroughly researched and analyzed labeling standards that FDA has 
already created and continues to create.  For example, there is currently more or less worldwide 
consensus that SPF labeling should be capped at “50+,” but the United States has yet to 
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affirmatively commit to this standard.
91  In spite of continually changing science, FDA has had 
many opportunities to codify regulations based on the best available science, which would have 
improved sunscreen labeling greatly.  Even in 2011, sunscreen labeling would likely be more 
helpful to the consumer if it adhered to the 1999 final monograph rather than the whims of 
manufacturers and advertising executives.  
This is not to say that any type of stay was inappropriate after the 1999 final monograph.  
The lack of an accepted standard to test UVA protection certainly created a gaping hole in the 
monograph.  For example, the monograph tied the issue of ingredient concentration levels to 
product performance, which was in turn evaluated based on the SPF level.
92  This decision was 
due to FDA’s decision to remove minimum concentration requirements for sunscreen active 
ingredients.
93  The new scheme would link the concentration directly to SPF, so that the 
concentration of each active ingredient must be sufficient to contribute to a minimum of SPF of 
two and the final SPF must be no less than the number of active ingredients multiplied by two.
94  
This amended requirement would ensure that each ingredient is actually useful to the 
effectiveness of the finished product, while also protecting against the needless inclusion of 
active ingredients to meet a minimum requirement.  Furthermore, this new requirement is more 
compatible with manufacturers’ creations of innovative formulation, which could also lower the 
risk of adverse reactions.
95   
At the same time, a product performance evaluation based solely on SPF is incomplete, 
as it ignores the important UVA component.    Before the final monograph was released, it was 
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suggested in a scholarly article that ingredient concentration levels should be based on total 
product performance, which would include a test for UVA protection.
96  This would very likely 
improve the FDA’s ability to maximize ingredient effectiveness by pinpointing with increased 
accuracy the desirable concentration levels of ingredients.  Thus, this specific issue would have 
benefited from extra time to sort through scientific data concerning UVA testing methods.   
Nonetheless, the stay was overinclusive.  It set aside labeling regulations that did not 
depend on new UVA radiation measurement data.  One could argue that it would cause more 
confusion to only stay part of the monograph rather than put the entire regulation on hold, but in 
fact, the FDA did only issue a partial stay.
97  Parts 310, 700, and 740 of the regulation were 
excluded from the stay.
98  These sections relate to FDA’s general administrative authority (part 
310) and the labeling and packaging of cosmetics (parts 700 and 740).
99  Thus, the agency 
showed its willingness to leave some regulations in tact, but still issued a sweeping stay of part 
352 of the regulation. 
Consequently, many of the labeling issues that currently exist could have been addressed 
before the UVA assessment technology was settled.  In fact, many of these issues were 
addressed, thoroughly analyzed, amended, and finalized, only to be stayed and rendered unfinal.  
For example, the word choice restrictions on water resistant claims could have been finalized 
without waiting for UVA testing to be further developed.  Even if FDA unwaveringly wanted to 
change the water resistant testing procedures to incorporate UVA protection, the actual word 
choice on the sunscreen label is independent of the testing mechanism.  In other words, whether 
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protection from water is described as “waterproof” or “water resistant” is unrelated to the actual 
test used.   
Similarly, the SPF cap of “30+” mandated in the final monograph is unrelated to UVA 
testing procedures.  While it is true that more data has been collected and examined since 1999, 
which has led FDA to raise the cap to “50+,”
100 the “30+” limit represented the best evidence at 
the time and would have helped to protect consumers from the false sense of security of an SPF 
85 sunscreen.  Additionally, the prohibition of the term “sunblock” could have been put into 
effect.  This word choice was not dependent on scientific testing procedures.  And even on the 
topic of UVA radiation, sunscreen products without any UVA protection could have been 
labeled as such.  This would have at least brought the UVA issue to the attention of consumers 
and could have helped people understand that SPF alone is not an indication of complete sun 
protection.  Indeed much of the subtle labeling does not concern UVA testing, and so the public 
has needlessly been deprived of clearer and less misleading labeling. 
While it is understandable that FDA wants to issue regulations that contain the best 
science and technology possible, this goal loses its benefits when finality and clarity are 
continually pushed further into the future.  Science is constantly progressing, and waiting for the 
absolute best testing methods to emerge is futile.  FDA has chosen to wait until 2007 to propose 
rules regulating the testing and labeling of UVA protection—and even longer to pass final 
binding regulations.  But even then, the science will not be complete.  Particularly in regards to 
UVA protection, many tests exist that can continue to be improved and modified to achieve more 
exact results. A recent study rated the status of sunscreen assessment and measurement at about 
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50% on the poor-to-perfect scale.
101  While many methods exist to assess sunscreens, the 
researchers concluded that more reliable and realistic methods were still far off from present 
capabilities.
102  The gains of scientific discovery are lost if the principles discovered are never 
put into action.  Even if the science of 1999 is imperfect, the failure to codify regulations based 
on those discoveries has left the public with far less protection. 
One direct effect of the sunscreen’s rulemaking process is that much confusion exists as 
to the current regulation of sunscreen.  The prolonged and unfinalized rulemaking, in addition to 
evasive statements by FDA, has led to confusion about the current standards governing 
sunscreen products on shelves today.  News articles available to the public make a wide range of 
assertions about the legal standards currently governing sunscreen labels, ranging from the 1978 
notice of rulemaking to the 1999 final monograph.
103  At an FDA press conference in 2007, the 
agency’s representatives struggled to explain the legal grey area that exists.  After two attempts 
at answering questions from the press regarding the status of the 1999 monograph, a third media 
correspondent stated, “I’m completely baffled by this 1999 Rule.  Was – did it never go into a 
test and why are manufacturers allowed to ignore it?”
104   
In fact, in the press conference about the proposed 2007 regulations, five questions were 
asked attempting to clarify the status of the 1999 rules.  An FDA representative attempted to 
clarify the issue by explaining why sunscreen SPF values above 30 are widely present in stores, 
stating that “[…] we have enforcement discretion where we have a rule out and we have – it 
hasn’t gone into effect yet.”
105  It is not surprising that others in attendance remained confused, 
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since “enforcement discretion” is an odd phrase to describe a rule that is not yet in effect.  Can 
manufacturers be legally bound to a regulation not yet in effect?  Later, an FDA representative 
stated, “after we find that [a sunscreen manufacturer’s] labeling deviates significantly from a 
proposed regulation such that it makes the product no longer safe and effective, we would take 
enforcement action against them.”
106  The speaker added, “we do have to prioritize our 
enforcement resources and we are most concerned about things that egregiously have safety 
concerns.”
107  This last statement is particularly peculiar, as FDA seems to defend the 
nonenforcement of the 1999 rules by pointing to the lack of resources rather than the lack of 
actually binding rules.  By emphasizing the agency’s enforcement discretion, the FDA 
representatives seemed anxious to avoid admitting that the 1999 rule was not in effect and that 
the many labeling conclusions made in the rule are free to be ignored, aside from serious safety 
concerns. 
At the same time, the FDA representatives did admit that “manufacturers are not required 
to comply with [the 1999 final rule].”
108  But they also added that manufacturers can voluntarily 
comply with the proposed regulations and oftentimes do voluntarily comply.
109  The explanation 
of the 1999 rule was delivered little by little in response to the five questions about the rule.  
Thus the FDA representatives begrudgingly described the nonbinding reality of the 1999 rule, 
while emphasizing discretion in special circumstances of safety concern to enforce the rule.  
Even after the five explanations of the 1999 rule, the FDA closed the press conference with 
ambiguity.  In response to a question asking what the ingredients of most sunscreens are today, 
the FDA representative responded, “There are 16 active ingredients in the 1999 Final Rule and 
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those are the same 16 active ingredients in this proposed rule today.”
110  This answer, of course, 
does not answer the question, but further highlights the evasive explanations of current sunscreen 
regulations. 
The lack of awareness of the public is likely due in part to the lack of implementation of 
final regulations.  The advertising of sunscreen products, in addition to campaigns led by health 
organizations and sunscreen issues discussed by the media, are the major influencing forces on 
public awareness.
111  FDA has stated that the reasons for the stay of the 1999 final monograph 
are distinct from whether the agency believes the information in the rule is accurate and 
reflective of current plans.
112  This admission highlights the problem.  By hoarding both 
conclusions and labeling improvement plans, FDA is effectively keeping information away from 
the public.  While most people have likely seen the label of a sunscreen bottle, they likely have 
not seen the text of the 1999 final monograph. 
As the public and industry continue to wait for final regulations, many issues continue to 
plague sunscreen labeling.  The current state of sunscreen bottles is far from in line with the 
standards set forth in the final monograph, in spite of FDA’s insistence that many manufacturers 
voluntarily have chosen to abide by the stayed regulations.
113  Without legally binding rules, it is 
hard to appreciate the incentive for lowering labeled SPF values and modifying claims to make 
the imperfections of sunscreen more readily apparent to customers.  In 2006 it was reported that 
more than 80% of marketed sunscreen products in the United States claimed some type of UVA 
protection, while only 56% contained a recognized UVA-1 filter.
114  Furthermore, terms such as 
“waterproof,” “sunblock,” and “SPF 85+” are free to appear on labels in spite of the fact that 
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FDA has acknowledged the misleading quality of such terms at least since 1999.
115  Such 
variability among standards hinders consumer protection and informed choice. 
Throughout all this time, lawmakers and the public have been getting impatient.  The 
SUN Act was introduced by Senator Dodd on May 20, 2009, but it was referred to the 
Committee on Health, Education, Labor, and Pensions with no further action taken.
116  This bill 
sought to force FDA action by legally enacting the 2007 proposed rules within 180 days of 
enactment of the SUN Act, unless FDA issued a final rule before that time.
117  In spite of general 
frustration, FDA has not finalized regulations.    
Perhaps what is most concerning, however, is the continued uncertainty of the future.  In 
response to the proposed rule released in 2007, the FDA has received over 3000 comments from 
the public.
118  Analyzing and responding to the comments’ concerns and suggestion is no easy 
task and should not be taken lightly.  However, this careful analysis has extended the timeline 
already and will likely continue to do so.  As of 2009, the International Organization for 
Standardization had been drafting standards for both SPF and UVA testing procedures.  Also in 
2009, Matthew Holman, the deputy director of the Division of Nonprescription Regulation 
Development, stated that FDA would not wait for international standards to be set and 
harmonized among countries before finalizing sunscreen regulations.
119  Instead, FDA would 
amend finalized regulations in the future, in light of finalized international standards.
120  This 
intention certainly seems to be the most prudent course of action, but FDA’s assertion to set 
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standards in light of uncertainty in the scientific community also seems at odds with the 
historical record of sunscreen regulation for the past few decades. 
 
Conclusion 
While FDA has made impressive changes to sunscreen labeling requirements in order to 
improve the knowledge and sun protection of the public, these changes are purely optional.  In 
reality, customers are faced with a wide variety of sunscreen products making a wide variety of 
claims and have little protection from FDA.  A great deal of time and effort has been put into 
sunscreen regulation, and it is a shame that this regulation has not been implemented.  A product 
as vital to health as sunscreen should be stringently regulated to better educate the public, and the 
label of the product is one of the most effective ways of reaching people.  The future of 
sunscreen regulation remains uncertain, and as the country continues to wait, the SPF 85+ 
waterproof sunblocks continue to fly off the drugstore shelves. 